Kyle Hoehn

Bayer Corp. manufactures and markets pharmaceutical, healthcare, nutrition and materials products. The firm offers consumer care, diagnostics, diabetes and animal health products. It also provides material science products, which include coating, adhesive and sealant raw materials polycarbonates polyurethanes and thermoplastic polyurethane elastomers. The company was founded in 1973 and is based in Whippany, NJ.

Cure DM, Inc. operates as a biopharmaceutical company. It develops new therapies that may prevent, ameliorate or reverse diabetes and allow for the discontinuation of insulin. The company was founded by Loraine V. Upham, Claresa S. Levetan and Rita El-Hajj in 2004 and is headquartered in Wilmington, DE.

Trafalgar Capital Management (UK) LLP (Trafalgar UK) is an alternative investment manager headquartered in London, UK. The firm was founded by Christopher Aarons in 2001 and is wholly-owned by Trafalgar Capital Management Ltd. Trafalgar UK manages separate hedge-based strategies.

Profil Institute for Clinical Research, Inc. operates as a full-service clinical research organization (CRO), that focuses on diabetes, obesity and NAFLD/NASH. It offers clinical development, regulatory affair, clinical research, scientific, data management and statistical, monitoring, quality and compliance, and recruitment services. The company was founded in 2004 and is headquartered in Chula Vista, CA.

Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life.

Trafalgar Capital Management (HK) Ltd. (Trafalgar HK) is a boutique investment management firm headquartered in Hong Kong. Formerly known as Megajoy Global Ltd., the firm was founded in 2010 and is owned by Trafalgar International Group SA in British Virgin Islands. Trafalgar HK manages two separate Hedge based strategies.

Segterra, Inc. engages in the development and marketing of a health and fitness analytics platform. It offers InsideTracker, which tracks and analyzes key biochemical and physiological markers and applies algorithms and scientific databases to determine personalized optimal zones for each marker. The company was founded by Richard Arnstein, Gil Blander, Christina Reich and David Lester in 2009 and is headquartered in Cambrdige, MA.

SphynKx Therapeutics LLC engages in developing, discovering and commercializing novel therapies for the treatment of fibrosis. Its Sphingosine 1-phosphate (S1P) is recognized as a key regulator of many of the cellular processes that promote wound healing and fibrogenesis, which include fibroblast and immune cell migration, vascular leak, proliferation, angiogenesis, and TGF-ß signaling. The company was founded by Andrew Bolt, Kevin R. Lynch, Webster Santos and Timothy L. Macdonald in 2010 and is headquartered in Charlottesville, VA.

EdenRoc Sciences LLC engages in the business of biotechnology. The company was founded in 2016 and is headquartered in Birmingham, MI.

JumpStart Fertility, Inc. operates in the health care industry. The company is headquartered in Chestnut Hill, MA.

Senolytic Therapeutics, Inc. engages in healthcare service. The company was founded in 2017 and is headquartered in Chestnut Hill, MA.

Life Biosciences, Inc. engages in the provision of research on aging and age-related diseases. It focuses on altered communication and inflammation, chromosomal instability, cellular senescence, loss of protoeostasis, metabolism, stem cell exhaustion, epigenetic alterations, and mitochondrial dysfunction. The company was founded by David Sinclair and Tristan Alexander Edwards in 2017 and is headquartered in Boston, MA.

ProSciento, Inc. is a full-service clinical research organization that works with biopharma companies worldwide to support their outsourced clinical research needs. The company is based in Chula Vista, CA, and has subsidiaries in the United States. The company specializes in providing comprehensive and customized services for multinational, early development clinical trial programs for metabolic continuum diseases, including diabetes, obesity, and steatotic liver disease. ProSciento has conducted over 300 clinical projects and supported the development of many approved metabolic drugs and devices on the market. ProSciento was founded in 2003, and Marcus Hompesch has been the CEO of the company since its inception.

Animal Biosciences, Inc. operates as a pre-commercialization and bio-pharmaceutical company. The firm develops therapeutics and supplements for pets, primarily dogs, cats and horses. The company was headquartered in Boston, MA.

Immetas Therapeutics, Inc. develops novel therapeutics that modulates the innate immune system to treat age-related cancers and inflammatory diseases. The company was founded by J. Gene Wang and David A. Sinclair in October 2018 and is headquartered in East Hanover, NJ.

Arc Bio LLC is an American company that is revolutionizing microbial detection by providing turnkey metagenomics solutions that combine a next-generation sequencing laboratory workflow with an automated bioinformatics pipeline. Arc Bio is based in an undisclosed location. The private company's Galileo™ platform empowers researchers and laboratorians to transition into the next era of infectious disease detection through an integrated set of easy-to-use, actionable genomics tools. The company aims to create a healthier world by delivering robust sample-to-report microbial profiling workflows combined with data-driven health intelligence software tools to enable a new standard of care for disease detection and monitoring. The company was founded by David Andrew Sinclair, Todd Dickinson, David Sinclair, and Carlos Bustamante. Todd Dickinson has been the CEO since incorporation.

Proto Axiom Pty Ltd. is an Australian company that focuses on investing in pre-clinical biotech companies to expand the growing bioscience industry. The company is based in Melbourne, Australia. The company has a disciplined and repeatable approach to investing by centralizing a world-class R & D team and licensing leading scientific IP to commercialize it. The company has an executive leadership with over 40 years of experience and a world-renowned scientific team with education from top academic institutions from across the globe, including Harvard. Despite Australia's strong biotech credentials, there is a distinct lack of early-stage venture capital funds to support and commercialize this science. The company was founded in 2021, and the CEO is Anthony Liveris.